Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
2023-09-18 07:57
The "Jiangsu-Germany Dialogue 2023" Held in Changzhou
2023-09-15 16:38
Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases
2023-09-14 23:00
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
2023-09-14 17:07
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
2023-09-14 16:54
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
2023-09-14 16:00
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
2023-09-13 19:09
Singleron launches AccuraCode® TCR library construction kit, enhancing efficiency and cost-effectiveness of high-throughput T-cell receptor profiling
2023-09-13 17:51
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
2023-09-13 15:58
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
2023-09-13 14:24
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7
2023-09-13 13:42
GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.
2023-09-13 00:00
Standigm's "Green Ribbon Campaign" to support Mitochondria Disease Awareness Week
2023-09-12 21:00
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
2023-09-12 19:24
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
2023-09-08 15:30
World Orphan Drug Alliance Welcomes Specialised Therapeutics
2023-09-08 04:00
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
2023-09-06 20:00
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
2023-09-06 19:00
CANbridge to Participate in Two Investor Conferences in September
2023-09-06 16:06
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
2023-09-05 20:00
1
40
41
42
43
44
222